



SURVIVAL RATES OF DOGS WITH LYMPHOMA MULTIPLIED BY 5.6 THANKS TO A THERAPEUTIC VACCINE IN IMMUNO-ONCOLOGY

Toulouse, 21st May 2019



Urodelia, a French biotech company and Italian veterinary oncology experts from the Universities of Milan, Turin and Bologna announce that positive results from 6 years of apa.vac® treatment on 300 dogs with B lymphoma will be presented at the ESVONC (European Society of Veterinary Oncology) congress, taking place May 23-25, 2019 in Frankfurt (Germany), by Dr. Laura Marconato, veterinary oncologist at Centro Oncologico Veterinario Srl in Bologna and an international expert in dogs' lymphomas treatments.

Urodelia's apa.vac® anticancer therapeutic vaccine was tested in combination with a chemotherapy in a six years study enrolling 300 dogs with B lymphoma. Results demonstrate that the co-treatment with apa.vac® prolonged survival rates compared to a conventional chemotherapy treatment and without side effects. For the overall population, the median survival rate is 401 days for animals that received the vaccine as co-treatment versus 220 days for those who received chemotherapy alone.

In a subgroup of dogs with B-DLBCL lymphoma, stage Va, with high LDH and without prior corticosteroid therapy, the co-treatment with apa.vac® was particularly relevant, with up to a 5.6-fold increase in the median survival rate compared to the conventional chemotherapy group.

"This is the largest study in terms of the number of dogs treated with the same protocol for a specific disease. This study confirms the safety and effectiveness of this protocol.", said Dr. Laura Marconato.

"This major study validates the efficacy of our apa.vac® vaccine in the treatment of cancer in animals.", added Nicole Rouquet, President of Urodelia.

About apa.vac®

Apa.vac® is an autologous therapeutic vaccine marketed in veterinary medicine. Based on the expertise of founders-associates in calcium phosphates chemistry and more specifically hydroxyapatite, Urodelia has developed an autologous vaccine in veterinary medicine whose concept is based on the association between tumour proteins purified from a biopsy of the animal's cancer cells and hydroxyapatite as a vector for immune stimulation.

About Urodelia

Urodelia is a French Biotech company specialized in the discovery and development of new anticancer treatments based on calcium phosphates strengthening the immune defenses of patients. Urodelia has developed and manufacture under the form of a kit an autologous vaccine apa.vac® prepared specifically for each patient. Apa.vac® kit is already distributed in 8 countries across Europe for veterinary indication. Urodelia's novel therapeutic approach offers the potential for fundamentally changing the way cancer is treated. For further information, please visit: <http://www.urodelia.com/en/>

For more information, please contact: Camille Bayol, Camille.bayol@urodelia.com